Stella Diagnostics

Early Stage

Optimizing Patient Management Strategies for Esophageal Diseases

Analytics

Raised to Date: Raised: $75,000

Aggregate Commitments $

Platform

Dalmore Group

Start Date

06/24/2021

Close Date

06/24/2022

Min. Goal

$5,000

Max. Goal

$20,000,000

Min. Investment

$5,000

Security Type

Equity - Preferred

Funding Type

RegA+

Price Per Share

$5.00

Rolling Commitments $

Status

Active

Reporting Date

05/27/2022

Days Remaining

28

% of Min. Goal

1,500%

% of Max. Goal

0%

Likelihood of Max
unlikely
Avg. Daily Raise

$223

Momentum
cold.svg
Log in or create a free account today to gain access to KingsCrowd analytics.
Location

Salt Lake City, Utah

Industry

Healthcare & Pharmaceuticals

Tech Sector

HealthTech

Stella Diagnostics is raising funds on Dalmore Group through Reg A+ crowdfunding. It is a molecular diagnostics company that is focused on improving patient management strategies for people living with the severe oesophageal disease. Stella Diagnostics’ mass spectrometric proteomic assays will help physicians study the molecular properties of patients’ tissues to determine if the disease is stable, progressing, or cancerous. Joe Abdo founded Stella Diagnostics in 1992. The current crowdfunding campaign has no minimum target and a maximum target of $20,000,000. The campaign proceeds will be used for product research, development, infrastructure-related costs, and administrative costs.

Balance Sheet

Cash and Cash Equivalents

$37,473

Investment Securities

$0

Total Investments

$0

Accounts and Notes Receivable

$0

Loans

$0

Property, Plant and Equipment (PP&E)

$0

Property and Equipment

$0

Total Assets

$39,807

Accounts Payable & Accrued Liabilities

$905,027

Policy Liabilities and Accruals

$0

Deposits

$0

Long Term Debt

$252,286

Total Liabilities

$10,585,028

Total Stockholders' Equity

$-10,545,221

Total Liabilities and Equity

$39,807

Statement of Comprehensive Income Information

Total Revenues

$0

Total Interest Income

$0

Costs & Expenses Applicable to Rev

$164,846

Total Interest Expenses

$0

Depreciation and Amortization

$0

Net Income

$-262,054

Earnings Per Share - Basic

$0

Earnings Per Share - Diluted

$0

Financials as of: 06/24/2021
Log in or create a free account today to gain access to KingsCrowd analytics.

Upgrade to gain access

Pay Monthly
Annually (Save 17%)

Starter

$8.33 /month
billed annually
Free portfolio tracking. Limited reports and filters.
Plan Includes:
Everything in Free, plus
Advanced company search ( limited filters)
Founder profiles and exclusive webinars
2 Analyst Reports per month
Get Starter Annual

Pro

$25 /month
billed annually
Unlimited analyst reports and market analytics.
Plan Includes:
Everything in Starter, plus
Full access to all Analyst Reports
Filter on Analyst Reports (e.g. Top Deal, Deal to Watch, etc.)
Market Analytics
Get Pro Annual

Merlin

$41.67 /month
billed annually
Full site access including KingsCrowd ratings.
Plan Includes:
Everything in Pro, plus
Search and filter companies by KingsCrowd ratings
Company specific KingsCrowd rating and risk assessment
Get Merlin Annual
Already a member? Log in here.

Analyst Report Analyst Report Methodology Article

Pending Review

Create your first portfolio

Create your very own investment portfolio on KingsCrowd.

Now you can track all of your startup investments in one place utilizing our state-of-the-art portfolio tracker tools. To begin, create your first portfolio below.

Add to portfolio
Stella Diagnostics on Dalmore Group 2022
$
Platform: Dalmore Group
Security Type: Equity - Preferred

Follow company

Follow Stella Diagnostics on Dalmore Group 2022
View on Dalmore Group
Bullish / Bearish
You're Bullish on Stella Diagnostics on Dalmore Group 2022

Thank you for your vote on Stella Diagnostics on Dalmore Group 2022

Bullish / Bearish
You're Bearish on Stella Diagnostics on Dalmore Group 2022

Thank you for your vote on Stella Diagnostics on Dalmore Group 2022